Tandem Diabetes Care Inc (NASDAQ:TNDM) Director Christopher J. Twomey purchased 75,000 shares of Tandem Diabetes Care stock in a transaction dated Friday, February 9th. The shares were acquired at an average cost of $2.00 per share, with a total value of $150,000.00. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Tandem Diabetes Care Inc (TNDM) traded up $0.02 during midday trading on Tuesday, hitting $2.43. 837,794 shares of the stock traded hands, compared to its average volume of 923,213. Tandem Diabetes Care Inc has a 12-month low of $2.14 and a 12-month high of $26.00. The stock has a market cap of $23.78, a price-to-earnings ratio of -0.12 and a beta of 0.44. The company has a quick ratio of 0.88, a current ratio of 1.90 and a debt-to-equity ratio of -2.70.
Several equities research analysts have recently commented on TNDM shares. Zacks Investment Research raised shares of Tandem Diabetes Care from a “hold” rating to a “buy” rating and set a $2.75 price target for the company in a research report on Wednesday, November 1st. Robert W. Baird reaffirmed a “hold” rating and set a $3.00 price target on shares of Tandem Diabetes Care in a research report on Sunday, November 19th. Five investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $11.29.
COPYRIGHT VIOLATION NOTICE: This article was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another publication, it was stolen and reposted in violation of US and international copyright law. The original version of this article can be viewed at https://www.americanbankingnews.com/2018/02/13/tandem-diabetes-care-inc-tndm-director-christopher-j-twomey-acquires-75000-shares.html.
About Tandem Diabetes Care
Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.